Repros Therapeutics, Inc. (RPRX)

[Dr Bill]

RPRX is still really undervalued here. Don't forget that this has the potential to be a blockbuster drug with not one but two applications. Both endometriosis and uterine fibroids are huge untapped markets worldwide.

That's not to say that the stock price won't decline but there are some big holders who would love to own more. Just give them the opportunity.

It's the waiting game that's tough.